Effects of glucocorticoids on traumatic brain injury related critical illness-related corticosteroid insufficiency  

作　　者：ZHAO Zi-long CHEN Xin ZHU Hui ZHANG Bao-liang CHAI Yan LI Xin-yuan DONG Jing-fei ZHANG Jian-ning 

机构地区：[1]Department of Neurosurgery, Tianjin Medical University General Hospital Key Laboratory of Post-trauma Neuro-repair and Regeneration in Central Nervous System, Ministry of Education Tianjin Key Laboratory of Injuries, Degeneration and Regeneration of Nervous System, Tianjin 300052, China [2]Tianjin Neurological Institute, Tianjin 30052, China [3]Department of Statistics, Tianjin Medical University, Tianjin 300070,China [4]Puget Sound Blood Research Institute, Department of Medicine University of Washington, Seattle 98104-1256, United States

出　　处：《Chinese Medical Journal》2013年第19期3754-3761,共8页中华医学杂志（英文版）

基　　金：This work was supported by grants from the National Natural Science Foundation of China （No. 81000533）, the Project of Tianjin Applied Basic and Cutting-edge Technological Research （No. 13JCQNJC10500） and National Key Basic Research Program in China （No. 2005CB522600）. Conflicts of interest： none.

摘　　要：Background Traumatic brain injury （TBI） is a heterogeneous condition that can lead to critical LLLness-related corticosteroid insufficiency （CIRCI） causing a high mortality and morbidity.Glucocorticoids were widely used in the clinical management of TBI,but their benefit has been challenged in some studies and their efficacy,especially for treating CIRCI in TBI patients,remains unclear.Methods We conducted a meta-analysis of published data to determine if the controversy is related to clinical dosing and timing of glucocorticoids （GCs） application.We analyzed published reports in four databases （MEDLINE,EMBASE,the Cochrane Controlled Trials Register,and CBMdisc）.The published data were stratified into not only low-and high-dose GCs group but also short-and long-term GCs group to compare their effectiveness in improving TBI outcomes.Results We totally identified 16 reports.For low-dose patients,the pooled relative risks （RRs） for two clinical outcomes of death or a combination of death and severe disability were 0.95 （95% confidence interval （CI）：0.80 to 1.13） and 0.95 （95% CI：0.83 to 1.09）,respectively.The risks for infection and gastrointestinal bleeding were 0.85 （95% CI：0.50 to 1.45） and 0.64 （95% Cl：0.15 to 2.70）,respectively.For high-dose group,the pooled RR of death is 1.14 （95% Cl：1.06 to 1.21）.The pooled RRs for infection and gastrointestinal bleeding for the high-dose patients were 1.04 （95% CI：0.93 to 1.15） and 1.26 （95% CI：0.92 to 1.75）,respectively.For long-term use group,the pooled RRs for two clinical outcomes of death or a combination of death and severe disability were 0.98 （95% CI：0.87 to 1.12） and 1.00 （95% CI：0.90 to 1.11）,respectively.The risks for infection and gastrointestinal bleeding were 0.88 （95% CI：0.71 to 1.11） and 0.96 （95% CI：0.35 to 2.66）,respectively.For short-term use group,the pooled RR of death is 1.15 （95% CI：1.07 to 1.23）,and importantly the effects on infections were beneficial in Background Traumatic brain injury （TBI） is a heterogeneous condition that can lead to critical LLLness-related corticosteroid insufficiency （CIRCI） causing a high mortality and morbidity.Glucocorticoids were widely used in the clinical management of TBI,but their benefit has been challenged in some studies and their efficacy,especially for treating CIRCI in TBI patients,remains unclear.Methods We conducted a meta-analysis of published data to determine if the controversy is related to clinical dosing and timing of glucocorticoids （GCs） application.We analyzed published reports in four databases （MEDLINE,EMBASE,the Cochrane Controlled Trials Register,and CBMdisc）.The published data were stratified into not only low-and high-dose GCs group but also short-and long-term GCs group to compare their effectiveness in improving TBI outcomes.Results We totally identified 16 reports.For low-dose patients,the pooled relative risks （RRs） for two clinical outcomes of death or a combination of death and severe disability were 0.95 （95% confidence interval （CI）：0.80 to 1.13） and 0.95 （95% CI：0.83 to 1.09）,respectively.The risks for infection and gastrointestinal bleeding were 0.85 （95% CI：0.50 to 1.45） and 0.64 （95% Cl：0.15 to 2.70）,respectively.For high-dose group,the pooled RR of death is 1.14 （95% Cl：1.06 to 1.21）.The pooled RRs for infection and gastrointestinal bleeding for the high-dose patients were 1.04 （95% CI：0.93 to 1.15） and 1.26 （95% CI：0.92 to 1.75）,respectively.For long-term use group,the pooled RRs for two clinical outcomes of death or a combination of death and severe disability were 0.98 （95% CI：0.87 to 1.12） and 1.00 （95% CI：0.90 to 1.11）,respectively.The risks for infection and gastrointestinal bleeding were 0.88 （95% CI：0.71 to 1.11） and 0.96 （95% CI：0.35 to 2.66）,respectively.For short-term use group,the pooled RR of death is 1.15 （95% CI：1.07 to 1.23）,and importantly the effects on infections were beneficial in

关 键 词：traumatic brain injury critical illness related corticosteroid insufficiency  mere-analysis stress-dose glucocorticoid 

分 类 号：R651.15[医药卫生—外科学]